FCPM III SERVICES B V
Q3 2026 Form 13-F
NAARDEN
CIK 0002013410
· Institutional investment manager
Consolidated report · includes
3 managers
since Q4 2023
$1.1B Reported Value Total
Reported value
$1.1B
Quarter over quarter
-26.5%
Holdings
15
Top-10 concentration
96.4%
Filing Structure
Reports holdings for
- Forbion Growth Management B.V. (not a 13F filer in our records) · File #028-24009 · since Q4 2023
- Forbion IV Management B.V. (not a 13F filer in our records) · File #028-24010 · since Q4 2023
- Forbion Growth Management III B.V. (not a 13F filer in our records) · File #028-26443 · since Q1 2026 · declared by one filing
- Forbion Growth Management III B.V. (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
- Forbion Growth Management II B.V. (not a 13F filer in our records) · File #028-25150 · Q1 2025 – Q3 2025 · declared by one filing
- Forbion Growth Management II B.V. (not a 13F filer in our records) · Q4 2024 – Q4 2024 · declared by one filing
Key People
Named on the latest Form 13-F filing — not necessarily an owner
M.a. Van Osch And G.j. Mulder
Directors
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $1.1B |
| Positions | 15 |
| Change in reported value | +41.4% |
| New positions | 4 |
| Exited positions | 0 |
| Position turnover | 26.7% |
| Top-10 concentration | 96.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
15 | $1.1B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
11 | $750.4M |
|
Q1 2026 13F
Filed May 15, 2026
|
10 | $722.2M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
10 | $762.9M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
9 | $500.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
8 | $369.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
7 | $413.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
8 | $592.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
7 | $582.3M |
|
Q2 2024 13F
Filed Aug 8, 2024
|
7 | $678.1M |
|
Q1 2024 13F
Filed May 3, 2024
|
6 | $707.3M |
|
Q4 2023 13F
Filed Mar 7, 2024
|
6 | $339.4M |
Top 15 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BRVE BRAVEHEART BIO INC | $440.9M | 41.57% |
| 2 | NAMS NEWAMSTERDAM PHARMA COMPANY | $206.5M | 19.47% |
| 3 | KRSA KORSANA BIOSCIENCES INC | $70.1M | 6.61% |
| 4 | VOR VOR BIOPHARMA INC | $65.0M | 6.13% |
| 5 | DYN DYNE THERAPEUTICS INC | $57.8M | 5.45% |
| 6 | GLTO DAMORA THERAPEUTICS INC | $51.9M | 4.9% |
| 7 | MPLT MAPLIGHT THERAPEUTICS INC | $45.1M | 4.25% |
| 8 | AURA AURA BIOSCIENCES INC | $33.0M | 3.11% |
| 9 | CBIO CRESCENT BIOPHARMA INC. | $29.5M | 2.78% |
| 10 | REPL REPLIMUNE GROUP INC | $22.8M | 2.15% |
| 11 | ENGN ENGENE HOLDINGS INC | $19.3M | 1.82% |
| 12 | BCYC BICYCLE THERAPEUTICS PLC | $12.8M | 1.2% |
| 13 | TARS TARSUS PHARMACEUTICALS INC | $5.0M | 0.47% |
| 14 | ENGNW ENGENE HOLDINGS INC | $575.6K | 0.05% |
| 15 | LSTA LISATA THERAPEUTICS INC | $428.4K | 0.04% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.